|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies:a phase I clinical study显示文摘Chimeric antigen receptor(CAR)-T cell therapy against T cell malignancies faces major challenges including fratricide between CAR-T cells and product contamination from the blasts.Allogeneic CAR-T cells,generated from healthy donor T cells,can provide ready-to-use,blast-free therapeutic products,but their application could be complicated by graft-versus-host disease(GvHD)and host rejection.Here we developed healthy donor-derived,CD7-targeting CAR-T cells(RD13-01)with genetic modifications to resist fratricide,GvHD and allogeneic rejection,as well as to potentiate antitumor function.A phase I clinical trial(NCT04538599)was conducted with twelve patients recruited(eleven with T cell leukemia/lymphoma,and one with CD7-expressing acute myeloid leukemia).All patients achieved pre-set end points and eleven proceeded to efficacy evaluation.No dose-limiting toxicity,GvHD,immune effector cell-associated neurotoxicity or severe cytokine release syndrome(grade≥3)were observed.28 days post infusion,81.8%of patients(9/11)showed objective responses and the complete response rate was 63.6%(7/11,including the patient with AML).3 of the responding patients were bridged to allogeneic hematopoietic stem cell transplantation.With a median follow-up of 10.5 months,4 patients remained in complete remission.Cytomegalovirus(CMV)and/or Epstein-Barr virus(EBV)reactivation was observed in several patients,and one died from EBV-associated diffuse large B-cell lymphoma(DLBCL).Expansion of CD7-negative normal T cells was detected post infusion.In summary,we present the first report of a Phase I clinical trial using healthy donor-derived CD7-targeting allogeneic CAR-T cells to treat CD7^(+)hematological malignancies.Our results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7^(+)tumors. | Yongxian Hu Yali Zhou Mingming Zhang Houli Zhao Guoqing Wei Wengang Ge Qu Cui Qitian Mu Gong Chen Lu Han Tingting Guo Jiazhen Cui Xiaoyan Jiang Xiujun Zheng Shuhui Yu Xiaolong Li Xingwang Zhang Mingxi Chen Xiuju Li Ming Gao Kang Wang Cheng Zu Hao Zhang Xiaohong He Yanbin Wang Dongrui Wang Jiangtao Ren He Huang | 2022 | Cell Research2022，32，11： | 2 |
| 2 | The solid-state synthesis of polyaniline/H4SiW12O40 materials 显示文摘 | Gong Jian Cui Xiujun Xie Zhongwei | 2002 | Synth Met2002，129，2： | 1 |
| 3 | Realizing a“solid to solid”process via in situ cathode electrolyte interface(CEI)by solvent-in-salt electrolyte for Li-S batteries显示文摘Lithium-sulfur batteries(LSBs)are regarded as the most promising next-generation energy system due to their high theoretical energy density.However,LSBs suffer the“shuttle effect”if undergoing the solid-liquid-solid sulfur conversion process during cycling.Herein,we design a solvent-in-salt(SIS)electrolyte with co-solvent vinylene carbonate(VC)to synthesize an in situ dense cathode electrolyte interface(CEI)and successfully change sulfur conversion into a solid-solid way to avoid shuttle effect by separating the contact of sulfur and ether solvent.Dense CEI is formed at the beginning of first discharge by the combined action of SIS electrolyte and filmogen VC.Experiments and simulations show that SIS electrolyte controls the initial formed lithium polysulfides(LiPSs)to stay very closely on the cathode surface,and then converts them into a dense CEI film.As a result,Coulombic efficiency(above 99%)and cycling performance of LSBs are improved.Furthermore,the in situ dense CEI can nearly stop the self-discharge of LSBs,and enable the LSBs to work under a pretty lean electrolyte condition. | Jiajun Huang Mengli Tao Weifeng Zhang Guangli Zheng Li Du Zhiming Cui Xiujun Wang Zhenxing Liang Shijun Liao Huiyu Song | 2023 | Nano Research2023，16，4： | 1 |
| 4 | Portable and automated analyzer for rapid and high precision in vitro dissolution of drugs显示文摘We developed a novel portable and automated dissolution test analyzer for rapid and high precision in vitro dissolution testing of drugs.The analyzer consists of a flow-through-cell drug dissolution system,an automated sequential sampling system,a high-speed capillary electrophoresis(HSCE)system,and a data acquisition system.Combining the high-temporal resolution flow-gating sampling approach with HSCE,which has outstanding advantages of efficient separation and resolution,the analyzer can achieve rapid analysis and exhibits the ability in miniaturization for on-site assessment of different active pharmaceutical ingredients.To integrate the flow-through-cell dissolution system with HSCE,a specially designed flow-gating-injection(FGI)interface was employed.The performance of the analyzer was investigated by analyzing the dissolution of immediate-release drugs including single dose(amoxicillin dispersible tablets)and fixed dose combination(amoxicillin and clavulanate potassium)drug tablets with the high-temporal resolutions of 12 s and 20 s,respectively.The dissolution profiles of different active pharmaceutical ingredients could be simultaneously and automatically monitored with high repeatability and accuracy.The analyzer was successfully utilized for the pharmaceutical quality control and bio-relevant dissolution testing,as well as in vivo-in vitro correlation analysis.Our portable analyzer is miniaturized,convenient and of low-cost,and will provide a valuable tool for dissolution testing in pharmaceutical research and development. | Zhongmei Chi Siqi Zhao Xiujun Cui Yunxiang Feng Li Yang | 2021 | Journal of Pharmaceutical Analysis2021，11，4： | 1 |
| 5 | The solid-state synthesis of polyaniline/H4SiW12O40 materials 显示文摘 | Gong Jian Cui Xiujun | 2002 | Synthetic Metals2002，129，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员